Relmada Therapeutics Reports Q1 Loss, Pivots Pipeline with New Asset Acquisition
RLMD has more than doubled off its 52-week low of $0.361.
Summary
Relmada Therapeutics reported a first-quarter 2026 net loss of $19.05 million, which widened from the prior year, though diluted loss per share improved to $(0.22). Crucially, the company announced a significant pipeline strategy shift, terminating REL-1017 and REL-P11, and acquiring sepranolone, a Phase 2b-ready asset targeting PWS and TS. Additionally, positive 12-month Phase 2 data for NDV-01 were reported, with Phase 3 trials planned for mid-2026. This 10-Q filing provides detailed financial results and operational updates following the major strategic shift and new financing announced in the company's March 2026 10-K, which resolved its going concern status and confirmed funding for at least 12 months. The pipeline pivot represents a material change in the company's R&D focus and future growth drivers, while the new asset and positive clinical data introduce fresh catalysts. Investors will monitor the progress of NDV-01 into planned Phase 3 trials and sepranolone into its Phase 2b study, as well as further developments in the company's in-licensing and acquisition strategy.
At the time of this announcement, RLMD was trading at $7.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $781.4M. The 52-week trading range was $0.36 to $8.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.